PMID

Data

Article Title

Organization

Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality.

Johnson & Johnson Pharmaceutical Research & Development

Structure-activity relationships for substrate-based inhibitors of human complement factor B.

The University Of Queensland

Profiling the enzymatic properties and inhibition of human complement factor B.

University Of Queensland

Discovery of 4-((2 S,4 S)-4-Ethoxy-1-((5-methoxy-7-methyl-1 H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases

Novartis Institutes For Biomedical Research

Chemical Approaches to Modulating Complement-Mediated Diseases.

The University Of Queensland

Macrocyclic peptidomimetic inhibitors of beta-secretase (BACE): first X-ray structure of a macrocyclic peptidomimetic-BACE complex.

Eli Lilly

Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. 6. 2-Indol-3-yl- and 2-azaindol-3-yl-dipyridodiazepinones.

Boehringer Ingelheim Pharmaceuticals

2',6'-Dimethylphenoxyacetyl: a new achiral high affinity P(3)-P(2) ligand for peptidomimetic-based HIV protease inhibitors.

Boehringer Ingelheim Pharmaceuticals